First patient enrolled in CHM CDH17 Phase 1/2 clinical trial
Filed with ASX · · 2 pages · English
Chimeric Therapeutics Limited on 6ix
In the deck
Earlier from Chimeric Therapeutics
- Phase 1b ADVENT-AML trial of CHM CORE-NK advances at MDA
- Chimeric opens CHM CDH17 Phase 1/2 trial
- CHM CDH17 Phase 1/2 clinical trial approved for initiation
- Resignation of CEO and Managing Director
- Clinical milestones for 2024 & 2023 successes highlighted
Later from Chimeric Therapeutics
- First patient dosed in Phase 1/2 trial of CHM CDH17
- Appendix 4E and Preliminary Final Report
- AML patient achieves Complete Response in CHM CORE-NK trial
- $5 million Placement to progress CHM CDH17 trial
- Reinstatement to Official Quotation
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics